216 related articles for article (PubMed ID: 15769814)
1. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
Grzeszczak W; Sulowicz W; Rutkowski B; de Vecchi AF; Scanziani R; Durand PY; Bajo A; Vargemezis V;
Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
[TBL] [Abstract][Full Text] [Related]
2. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
3. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
Mircescu G; Gârneată L; Ciocâlteu A; Golea O; Gherman-Căprioară M; Capsa D; Mota E; Gusbeth-Tatomir P; Ghenu A; Bălută S; Constantinovici N; Covic AC
Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
[TBL] [Abstract][Full Text] [Related]
4. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
12. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
13. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
Piccoli A; Malagoli A; Komninos G; Pastori G
J Nephrol; 2002; 15(5):565-74. PubMed ID: 12455725
[TBL] [Abstract][Full Text] [Related]
15. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
Bogdanos J; Karamanolakis D; Milathianakis K; Repousis P; Chloraki-Bobota A; Majed H; Pagalou-Thoua E; Tsintavis A; Koutsilieris M
Anticancer Res; 2004; 24(3b):1957-61. PubMed ID: 15274384
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.
Pirker R; Lehnert M; Minar W
Lung Cancer; 2007 Jan; 55(1):89-94. PubMed ID: 17084484
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
[TBL] [Abstract][Full Text] [Related]
19. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
Suzuki Y; Tokuda Y; Fujiwara Y; Minami H; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2008 Mar; 38(3):214-21. PubMed ID: 18296425
[TBL] [Abstract][Full Text] [Related]
20. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]